Nutra Pharma’s over the counter (OTC) products, Nyloxin® and Pet Pain-Away™, were featured on the NBC News Miami affiliate last night.
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that the Company and their products were featured in an interview aired last night on Miami’s NBC News affiliate (www.nbcmiami.com).
“NBC News has been featuring the use of natural products for the treatment of a variety of ailments,” commented Rik J Deitsch, CEO of Nutra Pharma. “For the most part, these reports have discussed the use of marijuana. Nutra Pharma’s Nyloxin has been shown to be just as potent as opiate pain relievers without the side effects caused by the use of opiates or marijuana,” he continued. “The report focusses on Nyloxin and Pet Pain-Away. These are clinically proven, legal and all-natural products that are available today to deal with pain and inflammation in people and their pets,” he concluded.
The interview was conducted by Jamie Guirola with filming at Nutra Pharma’s laboratory facility and the reptile farm that houses their cobras for venom production. Jamie, through his interviews, learned about cobra venom and its use as a potent pain-reliever (analgesic) and anti-inflammatory agent.
Nutra Pharma will announce further strategic business segment actions over the coming weeks. The Company expects to address Nyloxin® chronic pain solutions for the Sports-Athletic market as well as for Aging Individuals and Baby Boomers. Nutra Pharma is also addressing chronic pain in pets, especially dogs and cats, with Pet Pain-Away™.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets drug products for sale for the treatment of pain under the brand Nyloxin® and Pet Pain-Away™. For additional information about Nutra Pharma, visit:
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The news piece on NBC News should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.